Breadcrumb Home Business Activities Lundbeckfonden BioCapital Vtesse Pharma Vtesse Pharma Developed VTS-270 to treat patients with Niemann-Pick Disease Type C. Related news about Vtesse Pharma Sucampo Acquires Vtesse Inc. Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease Vtesse Announces Appointment of Jason Meyenburg as Chief Commercial Officer Vtesse Receives Rare Pediatric Disease Designation by the FDA for VTS-270 for the Treatment of Niemann-Pick Type C1 Disease Lundbeckfonden BioCapital Invested 2014 Acquired by Sucampo Pharmaceuticals in 2017 Location Gaithersburg, Maryland, USA
